Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Howard Hughes Medical Institute is currently managing 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 6 pending office actions are distributed among 6 distinct examiners, which indicates that each active case is being evaluated by a different individual. This distribution means that the company prosecution experience is not concentrated under 1 official.
The busiest examiner for this portfolio is PERSONS, JENNA L, who is responsible for 1 pending office action. Since the total of 6 pending office actions is spread across 6 distinct examiners, PERSONS, JENNA L handles a portion of the workload that is equal to the other examiners involved. This creates a decentralized prosecution environment where the company must address the specific feedback of 6 different people.
The involvement of 5 distinct art units means that the technical review is conducted across different specialized groups at the patent office. With 6 distinct examiners and 5 distinct art units, the company must navigate various procedural preferences and technical standards. The company must tailor its responses to the specific requirements of the 5 distinct art units involved in the prosecution of these cases.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (33%) |
| §112 only | 1 (17%) |
| Double-patenting + other | 2 (33%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PERSONS, JENNA L | 1 | 50.8% | +61.7% |
| LUU, THANH X | 1 | 78.2% | +10.2% |
| WANG, MICHAEL H | 1 | 52.1% | +25.5% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
| REGA, KYLE THOMAS | 1 | 62.7% | +41.4% |
| OGUNTADE, ELIZABETH BISOLA | 1 | 0.0% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18390289 | COMPOUNDS AND COMPOSITIONS COMPRISING FLUOROPHORES FOR USE IN VISUALIZATION AND PURIFICATION OR MANIPULATION | WILLIS, DOUGLAS M | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17553725 | ENGINEERED OPIOID BIOSENSORS | OGUNTADE, ELIZABETH BISOLA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19529937 | MODIFIED LIGAND-GATED ION CHANNELS AND METHODS OF USE | PERSONS, JENNA L | — |
| 18986227 | PHASE DIVERSITY-BASED WAVEFRONT SENSING FOR FLUORESCENCE MICROSCOPY | LUU, THANH X | — |
| 18953535 | PASSIVE VOLUNTARY POSITIONING OF ANIMAL FOR MICROSCOPY | WANG, MICHAEL H | — |
| 18390289 | COMPOUNDS AND COMPOSITIONS COMPRISING FLUOROPHORES FOR USE IN VISUALIZATION AND PURIFICATION OR MANIPULATION | WILLIS, DOUGLAS M | — |
| 18318997 | TRYPTOPHAN-CONTAINING CHEMIGENETIC FLUORESCENT INDICATOR | REGA, KYLE THOMAS | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| 3642 | 1 |
| 1624 | 1 |
| 1636 | 1 |
| 1677 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19529937 | MODIFIED LIGAND-GATED ION CHANNELS AND METHODS OF USE | PERSONS, JENNA L | 1637 | §102§103§112DP | Non-Final OA | — | Pending | Feb 04, 2026 |
| 18986227 | PHASE DIVERSITY-BASED WAVEFRONT SENSING FOR FLUORESCENCE MICROSCOPY | LUU, THANH X | — | §103 | Non-Final OA | — | Pending | Dec 18, 2024 |
| 18953535 | PASSIVE VOLUNTARY POSITIONING OF ANIMAL FOR MICROSCOPY | WANG, MICHAEL H | 3642 | §103 | Final Rejection | — | Pending | Nov 20, 2024 |
| 18390289 | COMPOUNDS AND COMPOSITIONS COMPRISING FLUOROPHORES FOR USE IN VISUALIZATION AND PURIFICATION OR MANIPULATION | WILLIS, DOUGLAS M | 1624 | §112 | Final Rejection | — | Pending | Dec 20, 2023 |
| 18318997 | TRYPTOPHAN-CONTAINING CHEMIGENETIC FLUORESCENT INDICATOR | REGA, KYLE THOMAS | 1636 | §103§112DP | Non-Final OA | — | Pending | May 17, 2023 |
| 17553725 | ENGINEERED OPIOID BIOSENSORS | OGUNTADE, ELIZABETH BISOLA | 1677 | §102§112 | Final Rejection | — | Pending | Dec 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial